Press Coverage
2009-12-11: (ProteoMonitor) The Biomarkers That Could: How Five Biomarkers Might Be the Key to Vermillion's turnaround
By becoming the first proteomics IVDMIA to gain FDA clearance, Vermillion’s OVA1 ovarian cancer test might be the key to Vermillion’s success. SELDI, a key component in the Lucid Proteomics System, is the technology that powered the development and validation of the test.
2009-12-07: (Drug Discovery and Development) Bottom-Up or Top-Down?
A review of methodologies for biomarker discovery and identification, including the Lucid Proteomics System.
2009-08-08: (sp2 Magazine) A New Combined Approach in Biomarker Discovery
Researchers can use the Lucid Proteomics System to access the full range of proteins that may lead to clinically relevant biomarkers.
2009-06-05: (ProteoMonitor) New Technology Combining Bruker's MALDI-TOF/TOF with Bio-Rad's SELDI Set to Launch
Bruker and Bio-Rad Laboratories launch the Lucid Proteomics System, which links Bruker's MALDI-TOF/TOF platform with Bio-Rad's SELDI technology to enable researchers to detect a class of proteins and peptides that other technologies have tripped over.
